A phase III randomised, stratified, parallel-group, multicentre, comparative study of ZD1839 [gefitinib; Iressa] 250mg and 500mg versus methotrexate for previously treated patients with squamous cell carcinoma of the head and neck

Trial Profile

A phase III randomised, stratified, parallel-group, multicentre, comparative study of ZD1839 [gefitinib; Iressa] 250mg and 500mg versus methotrexate for previously treated patients with squamous cell carcinoma of the head and neck

Completed
Phase of Trial: Phase III

Latest Information Update: 10 Nov 2015

At a glance

  • Drugs Gefitinib; Methotrexate
  • Indications Head and neck cancer
  • Focus Therapeutic Use
  • Acronyms IMEX
  • Most Recent Events

    • 22 Mar 2009 Primary endpoint 'Overall Survival' has not been met.
    • 22 Mar 2009 Results have been published in the Journal of Clinical Oncology (online).
    • 17 Oct 2007 Status changed from in progress to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top